Get data-driven insight into key biopharma trends
This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape.
Access your complimentary copy for actionable intelligence on regulatory shifts, M&A activity, dealmaking trends, market events and more.
WHAT’S IN THE PACK?
Regulatory rejection flurry does not make a storm
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Another big year beckons for biotech venture financing
Private drug developers have already raised more money this year than in 2020.
Private drug developers have already raised more money this year than in 2020.
Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall, 2021 has been quiet on the takeover front.
M&A picked up in the third quarter but overall, 2021 has been quiet on the takeover front.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
